异吲哚啉酮化合物

By binding isoindolinone compounds to the E3 ligase hydroxycerebroside, specific degradation of GSPT1 is achieved, overcoming the shortcomings of existing technologies in the treatment of solid tumors and neuroendocrine cancers, and demonstrating significant therapeutic effects on a variety of cancers.

CN117242060BActive Publication Date: 2026-07-17MONTE ROSA THERAPEUTICS INC

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
MONTE ROSA THERAPEUTICS INC
Filing Date
2022-01-13
Publication Date
2026-07-17

Smart Images

  • Figure CN117242060B_ABST
    Figure CN117242060B_ABST
Patent Text Reader

Abstract

本文公开了式(I)的化合物或其药学上可接受的盐或立体异构体。这些化合物可用作羟脑苷脂的调节剂,特别是用于治疗哺乳动物体内,尤其人体内的异常细胞生长。
Need to check novelty before this filing date? Find Prior Art